Centre for Big Data Research in Health, Faculty of Medicine, UNSW Sydney, Sydney, Australia.
Infection and Immunity, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia.
Br J Clin Pharmacol. 2022 Mar;88(3):1143-1151. doi: 10.1111/bcp.15000. Epub 2021 Aug 17.
Public health responses to reduce SARS-CoV-2 transmission have profoundly affected the epidemiology and management of other infections. We examined the impact of COVID-19 restrictions on antibiotic dispensing in Australia.
We used national claims data to investigate antibiotic dispensing trends from November 2015 to October 2020 and whether changes reflected reductions in primary care consultations. We used interrupted time series analysis to quantify changes in monthly antibiotic dispensing and face-to-face and telehealth GP consultations and examined changes by recipient age, pharmacy State and prescriber specialty.
Over the study period, an estimated 19 921 370 people had 125 495 137 antibiotic dispensings, 71% prescribed by GPs. Following COVID-19 restrictions, we observed a sustained 36% (95% CI: 33-40%) reduction in antibiotic dispensings from April 2020. Antibiotics recommended for managing respiratory tract infections showed large reductions (range 51-69%), whereas those recommended for non-respiratory infections were unchanged. Dispensings prescribed by GPs decreased from 63.5 per 1000 population for April-October 2019 to 37.0 per 1000 for April-October 2020. Total GP consultation rates remained stable, but from April 2020, 31% of consultations were telehealth.
In a setting with a low COVID-19 incidence, restrictions were associated with a substantial reduction in community dispensings of antibiotics primarily used to treat respiratory infections, coincident with reported reductions in respiratory viral infections. Our findings are informative for post-pandemic antimicrobial stewardship and highlight the potential to reduce inappropriate prescribing by GPs and specialists for respiratory viral infections.
为减少 SARS-CoV-2 传播而采取的公共卫生措施对其他感染的流行病学和管理产生了深远影响。我们研究了 COVID-19 限制措施对澳大利亚抗生素配药的影响。
我们使用国家索赔数据,调查了 2015 年 11 月至 2020 年 10 月期间抗生素配药趋势,以及变化是否反映了初级保健咨询减少。我们使用中断时间序列分析来量化每月抗生素配药以及面对面和远程医疗 GP 咨询的变化,并按收件人年龄、药房州和开方医生专业检查变化。
在研究期间,估计有 19921370 人接受了 125495137 次抗生素配药,其中 71%由全科医生开具。COVID-19 限制措施实施后,我们观察到 2020 年 4 月以来抗生素配药持续减少 36%(95%CI:33-40%)。用于治疗呼吸道感染的抗生素的用量大幅减少(范围 51-69%),而非呼吸道感染的抗生素用量则保持不变。2019 年 4 月至 10 月,全科医生每 1000 人开具的抗生素处方从 63.5 降至 2020 年 4 月至 10 月的 37.0。全科医生的总咨询率保持稳定,但从 2020 年 4 月起,31%的咨询是远程医疗。
在 COVID-19 发病率较低的环境中,限制措施与主要用于治疗呼吸道感染的社区抗生素配药大幅减少相关,这与呼吸道病毒感染减少的报道一致。我们的研究结果为大流行后抗菌药物管理提供了信息,并强调了减少全科医生和专科医生对呼吸道病毒感染的不当处方的潜力。